GSEP
KPTI icon

Golden State Equity Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Golden State Equity Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-120
Closed -$1.49K – 666
2024
Q3 		$1.49K Buy
+120
New +$1.49K ﹤0.01% 722
2022
Q1 		$308K Hold
2,790
– – 0.16% 149
2021
Q4 		$269K Buy
2,790
+793
+40% +$79K 0.14% 141
2021
Q3 		$174K Buy
1,997
+523
+35% +$54.3K 0.07% 222
2021
Q2 		$228K Buy
1,474
+761
+107% +$110K 0.09% 216
2021
Q1 		$113K Buy
+713
New +$150K 0.06% 164

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Golden State Equity Partners's KPTI Position: Q4 2024 in Review

Golden State Equity Partners sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 120 shares — an estimated $1.49K sold.

Golden State Equity Partners first reported a position in KPTI in Q1 2021 and held it in 6 quarters. The position peaked at $308K in Q1 2022. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

  • Golden State Equity Partners reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 120 Karyopharm Therapeutics shares in Q4 2024, an estimated $1.49K.
  • Golden State Equity Partners first reported a position in Karyopharm Therapeutics in Q1 2021 and held it in 6 quarters.
  • Golden State Equity Partners's Karyopharm Therapeutics position peaked at $308K in Q1 2022.
  • 87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.